A Nanobody Activation Immunotherapeutic That Selectively Destroys HER2-Positive Breast Cancer Cells

ChemBioChem - Germany
doi 10.1002/cbic.201500591
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2012English

Selective Cytotoxicity to HER2 Positive Breast Cancer Cells by Saporin-Loaded Nanobody-Targeted Polymeric Nanoparticles in Combination With Photochemical Internalization

Molecular Pharmaceutics
Drug DiscoveryMolecular MedicinePharmaceutical Science
2019English

Modulating Cancer Stemness Provides Luminal a Breast Cancer Cells With HER2 Positive-Like Features

Journal of Cancer
Oncology
2020English

Targeted Therapy for HER2 Positive Breast Cancer

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

Cancer Research
Cancer ResearchOncology
2009English

Effects of Herceptin on Circulating Tumor Cells in HER2 Positive Early Breast Cancer

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2015English

Optimal Treatment of Early Stage HER2-positive Breast Cancer

Cancer
Cancer ResearchOncology
2018English

Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer

Scientific Reports
Multidisciplinary
2017English

Current Neoadjuvant Treatment Options for HER2 Positive Breast Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy